ClariVest Asset Management LLC grew its position in BioTelemetry Inc (NASDAQ:BEAT) by 176.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 56,936 shares of the medical research company’s stock after purchasing an additional 36,336 shares during the period. ClariVest Asset Management LLC’s holdings in BioTelemetry were worth $3,400,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Miles Capital Inc. raised its stake in shares of BioTelemetry by 1.9% in the fourth quarter. Miles Capital Inc. now owns 8,006 shares of the medical research company’s stock valued at $478,000 after acquiring an additional 152 shares during the period. State of Alaska Department of Revenue raised its stake in shares of BioTelemetry by 2.3% in the fourth quarter. State of Alaska Department of Revenue now owns 11,132 shares of the medical research company’s stock valued at $664,000 after acquiring an additional 245 shares during the period. Bank of Montreal Can raised its stake in shares of BioTelemetry by 29.1% in the fourth quarter. Bank of Montreal Can now owns 1,924 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 434 shares during the period. Financial Architects Inc purchased a new stake in shares of BioTelemetry in the fourth quarter valued at $30,000. Finally, We Are One Seven LLC purchased a new stake in shares of BioTelemetry in the fourth quarter valued at $44,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Heather C. Getz sold 10,590 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $70.41, for a total transaction of $745,641.90. Following the completion of the transaction, the vice president now directly owns 80,661 shares of the company’s stock, valued at $5,679,341.01. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Heather C. Getz sold 64,989 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $70.09, for a total value of $4,555,079.01. Following the transaction, the chief financial officer now directly owns 119,085 shares of the company’s stock, valued at $8,346,667.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 177,198 shares of company stock valued at $12,419,736. Corporate insiders own 8.30% of the company’s stock.

BEAT has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a report on Monday. Sidoti set a $95.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. BidaskClub lowered shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Raymond James decreased their price objective on shares of BioTelemetry from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Wednesday, October 31st. Finally, ValuEngine raised shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. BioTelemetry has a consensus rating of “Buy” and a consensus price target of $70.57.

Shares of NASDAQ:BEAT opened at $76.30 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.50 and a current ratio of 2.68. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of 78.66, a price-to-earnings-growth ratio of 4.16 and a beta of 1.75. BioTelemetry Inc has a 1 year low of $29.85 and a 1 year high of $80.92.

TRADEMARK VIOLATION NOTICE: “BioTelemetry Inc (BEAT) Stake Raised by ClariVest Asset Management LLC” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/biotelemetry-inc-beat-stake-raised-by-clarivest-asset-management-llc/2819466.html.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.